Kiora Pharmaceuticals (KPRX) Enterprise Value (2016 - 2025)
Kiora Pharmaceuticals' Enterprise Value history spans 11 years, with the latest figure at -$17.1 million for Q4 2025.
- For Q4 2025, Enterprise Value rose 36.2% year-over-year to -$17.1 million; the TTM value through Dec 2025 reached -$17.1 million, up 36.2%, while the annual FY2025 figure was -$17.1 million, 36.2% up from the prior year.
- Enterprise Value reached -$17.1 million in Q4 2025 per KPRX's latest filing, up from -$19.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$2.5 million in Q4 2023 to a low of -$31.3 million in Q1 2024.
- Average Enterprise Value over 5 years is -$13.5 million, with a median of -$8.0 million recorded in 2023.
- Peak YoY movement for Enterprise Value: soared 56.5% in 2022, then plummeted 989.57% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$7.9 million in 2021, then skyrocketed by 38.6% to -$4.9 million in 2022, then surged by 49.31% to -$2.5 million in 2023, then tumbled by 989.57% to -$26.8 million in 2024, then soared by 36.2% to -$17.1 million in 2025.
- Per Business Quant, the three most recent readings for KPRX's Enterprise Value are -$17.1 million (Q4 2025), -$19.4 million (Q3 2025), and -$20.7 million (Q2 2025).